Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Pancreatic cancer (PC) is one of the most lethal cancers worldwide, but there are currently no effective treatments. The DNA damage response (DDR) is under investigation for the development of novel anti-cancer drugs. Since DNA repair pathway alterations have been found frequently in PC, the purpose of this study was to test the DDR-targeting strategy in PC using WEE1 and ATM inhibitors. Materials and Methods We performed in vitro experiments using a total of ten human PC cell lines to evaluate antitumor effect of AZD1775 (WEE1 inhibitor) alone or combination with AZD0156 (ATM inhibitor). We established Capan-1–mouse model for in vivo experiments to confirm our findings. Results In our research, we found that WEE1 inhibitor (AZD1775) as single agent showed anti-tumor effects in PC cells, however, targeting WEE1 upregulated p-ATM level. Here, we observed that co-targeting of WEE1 and ATM acted synergistically to reduce cell proliferation and migration, and to induce DNA damage in vitro. Notably, inhibition of WEE1 or WEE1/ATM downregulated programmed cell death ligand 1 expression by blocking glycogen synthase kinase-3! serine 9 phosphorylation and decrease of CMTM6 expression. In Capan-1 mouse xenograft model, AZD1775 plus AZD0156 (ATM inhibitor) treatment reduced tumor growth and downregulated tumor expression of programmed cell death ligand 1, CMTM6, CD163, and CXCR2, all of which contribute to tumor immune evasion. Conclusion Dual blockade of WEE1 and ATM might be a potential therapeutic strategy for PC. Taken together, our results support further clinical development of DDR-targeting strategies for PC.
Abstract
Purpose Pancreatic cancer (PC) is one of the most lethal cancers worldwide, but there are currently no effective treatments. The DNA damage response (DDR) is under investigation for the development of novel anti-cancer drugs. Since DNA repair pathway alterations have been found frequently in PC, the purpose of this study was to test the DDR-targeting strategy in PC using WEE1 and ATM inhibitors. Materials and Methods We performed in vitro experiments using a total of ten human PC cell lines to evaluate antitumor effect of AZD1775 (WEE1 inhibitor) alone or combination with AZD0156 (ATM inhibitor). We established Capan-1–mouse model for in vivo experiments to confirm our findings. Results In our research, we found that WEE1 inhibitor (AZD1775) as single agent showed anti-tumor effects in PC cells, however, targeting WEE1 upregulated p-ATM level. Here, we observed that co-targeting of WEE1 and ATM acted synergistically to reduce cell proliferation and migration, and to induce DNA damage in vitro. Notably, inhibition of WEE1 or WEE1/ATM downregulated programmed cell death ligand 1 expression by blocking glycogen synthase kinase-3! serine 9 phosphorylation and decrease of CMTM6 expression. In Capan-1 mouse xenograft model, AZD1775 plus AZD0156 (ATM inhibitor) treatment reduced tumor growth and downregulated tumor expression of programmed cell death ligand 1, CMTM6, CD163, and CXCR2, all of which contribute to tumor immune evasion. Conclusion Dual blockade of WEE1 and ATM might be a potential therapeutic strategy for PC. Taken together, our results support further clinical development of DDR-targeting strategies for PC.
참고문헌 (33)
- Bailey P, "Genomic analyses identify molecular subtypes of pancreatic cancer", Nature, 531, pp.47~52 (2016)
- 최연악, "Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study", Cancer Research and Treatment, 48(3), pp.1045~1055 (2016), 대한암학회
- O’Connor MJ, "Targeting the DNA damage response in cancer", Mol Cell, 60, pp.547~560 (2015)
- Richer AL, "WEE1 kinase inhibitor AZD1775 has preclinical efficacy in LKB1-deficient non-small cell lung cancer", Cancer Res, 77, pp.4663~4672 (2017)
- Kaufman B, "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1", 2mutation, 2015, pp.33, 244~250
- Chen CC, "ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair", Proc Natl Acad Sci U S A, 114, pp.7665~7670 (2017)
- Mohni KN, "ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency", Cancer Res, 74, pp.2835~2845 (2014)
- Matheson CJ, "Targeting WEE1 kinase in cancer", Trends Pharmacol Sci, 37, pp.872~881 (2016)
- Binnewies M, "Understanding the tumor immune microenvironment(TIME)for effective therapy", Nat Med, 24, pp.541~550 (2018)
- Steele CW, "CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma", Cancer Cell, 29, pp.832~845 (2016)
- Chen DS, "Oncology meets immunology : the cancer-immunity cycle", Immunity, 39, pp.1~10 (2013)
- Burr ML, "CMTM6 maintains the expression of PD-L1and regulates anti-tumour immunity", Nature, 549, pp.101~105 (2017)
- Chatzinikolaou G, "DNA damage and innate immunity : links and trade-offs", Trends Immunol, 35, pp.429~435 (2014)
- Rosado MM, "Beyond DNA repair, the immunological role of PARP-1 and its siblings", Immunology, 139, pp.428~437 (2013)
- Sato H, "DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells", Nat Commun, 8, pp.1751~ (2017)
- Jiao S, "PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression", Clin Cancer Res, 23, pp.3711~3720 (2017)
- Farina AR, "Gelatinase B", MMP-9 in tumour pathogenesis and progression, 2014, pp.6, 240~296
- Gialeli C, "Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting", FEBS J, 278, pp.16~27 (2011)
- Zarogoulidis P, "Interleukin-8 and interleukin-17 for cancer", Cancer Invest, 32, pp.197~205 (2014)
- Chuang JY, "CCL5", CCR5 axis promotes the motility of human oral cancer cells, 2009, pp.220, 418~426
- Tang CH, "CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras", Raf, ERK, pp.NF-!B signaling pathway, Biochem Pharmacol[DOI]
- Topalian SL, "Immune checkpoint blockade : a common denominator approach to cancer therapy", Cancer Cell, 27, pp.450~461 (2015)
- Li CW, "Glycosylation and stabilization of programmed death ligand-1suppresses T-cell activity", Nat Commun, 7, pp.12632~ (2016)
- Pilie PG, "State-of-the-art strategies for targeting the DNA damage response in cancer", Nat Rev Clin Oncol, 16, pp.81~104 (2019)
- Chen D, "Wee1 inhibitor AZD1775 combined with cisplatin potentiates anticancer activity against gastric cancer by increasing DNA damage and cell apoptosis", Biomed Res Int, 2018, pp.5813292~ (2018)
- Chen WT, "ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion", Elife, 4, pp.e07270~ (2015)
- Dalton HJ, "Monocyte subpopulations in angiogenesis", Cancer Res, 74, pp.1287~1293 (2014)
- Kolli-Bouhafs K, "FAK competes for Src to promote migration against invasion in melanoma cells", Cell Death Dis, 5, pp.e1379~ (2014)
- Zhang ZX, "CREB promotes laryngeal cancer cell migration via MYCT1", NAT10axis, 2018, pp.11, 1323~1331
- Garcia-Diaz A, "Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression", Cell Rep, 19, pp.1189~1201 (2017)
- Asgarova A, "PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in nonsmall cell lung carcinoma", Oncoimmunology, 7, pp.e1423170~ (2018)
- Wang H, "HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity", Nat Chem Biol, 15, pp.42~50 (2019)
- Aras S, "TAMeless traitors : macrophages in cancer progression and metastasis", Br J Cancer, 117, pp.1583~1591 (2017)